The BASE-ACS randomized controlled trial

The BASE-ACS randomized controlled trial is a randomized controlled trial comparing the Titan2 bioactive (Stainless steel platform) stent against the world leader 2^nd generation Drug-eluting stent Xience, from Abbott in ACS (STEMI/NSTEMI) patients at 12 months and 60 months follow ups.

Study Design:

• Multi-center, international, prospective, randomized, controlled trial
• 14 sites
• 827 patients
• Primary Efficacy Endpoint: MACE at 12 months (cardiac death, MI or TLR)
• Secondary Endoints : individual components of the primary endpoint, rate of thrombosis
• Follow-up 18 & 60 months

Key Findings at 12 months follow ups:

The clinical trial met its primary endpoint of MACE non-inferiority at 12 month. The TiTAN2 TiNO coated bioactive stent achieved a low 9.6% MACE rate compared to 9.0% for Xience DES (p for non-inferiority = 0.001).